February 4, 2015 - AVAC
Today the Microbicide Trials Network (MTN) research team published the final VOICE trial results in the New England Journal of Medicine with findings that add urgency, and perhaps optimism, to the women's HIV prevention field as it counts the days until the late-February release of data from the FACTS 001 trial of the 1% tenofovir microbicide gel. (There is also a journal commentary entitled Preventing HIV in Women — Still Trying to Find Their VOICE.)
How does a publication of a trial that reported its results two years ago (and ended gel randomization and placebo control three years ago) raise the stakes today? To answer that question, it helps to look back at VOICE's design and findings to date. Continue reading...